In-vitro activity of nisin against clinical isolates of Clostridium difficile

被引：64
作者：
Bartoloni, A
Mantella, A
Goldstein, BP
Dei, R
Benedetti, M
Sbaragli, S
Paradisi, F
机构：
[1] Univ Florence, Clin Malattie Infett, Osped Careggi, I-50134 Florence, Italy
[2] AMBL Inc, Purchase, NY 10577 USA
[3] Univ Florence, Sez Microbiol, Dipartimento Sanita Pubbl, I-50134 Florence, Italy
来源：
JOURNAL OF CHEMOTHERAPY | 2004年 / 16卷 / 02期
关键词：
nisin; Clostridium difficile; peptide antibiotics; hospital-acquired diarrhea;
D O I：
10.1179/joc.2004.16.2.119
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nisin is a cationic peptide produced by Lactococcus lactis. Its activity against clinical isolates of Clostridium difficile was compared to that of vancomycin and metronidazole by minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and time-kill studies. Nisin was more active than the other agents, with a MIC90 of 0.256 mg/L and strong bactericidal activity. Nisin may be a promising agent for the management of C. difficile associated diarrhea.
引用
收藏
页码：119 / 121
页数：3
相关论文
共 12 条
[1]  
ALLEN SD, 1999, MANUAL CLIN MICROBIO
[2]   Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997 [J].
Barbut, F ;
Decré, D ;
Burghoffer, B ;
Lesage, D ;
Delisle, F ;
Lalande, V ;
Delmée, M ;
Avesani, V ;
Sano, N ;
Coudert, C ;
Petit, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2607-2611
[3]   Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic [J].
Breukink, E ;
Wiedemann, I ;
van Kraaij, C ;
Kuipers, OP ;
Sahl, HG ;
de Kruijff, B .
SCIENCE, 1999, 286 (5448) :2361-2364
[4]   OBSERVATIONS ON PHAGE-TYPING OF CLOSTRIDIUM-DIFFICILE - PRELIMINARY EVALUATION OF A PHAGE PANEL [J].
DEI, R .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1989, 5 (03) :351-354
[5]  
FEKETY R, 1996, CECIL TXB MED, P1633
[6]   Peptide antibiotics [J].
Hancock, REW ;
Chapple, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1317-1323
[7]   Activity of nisin against Clostridium difficile [J].
Kerr, KG ;
Copley, RM ;
Wilcox, MH .
LANCET, 1997, 349 (9057) :1026-1027
[8]  
National Committee for Clinical Laboratory Standard, 1997, M11A4 NCCLS
[9]   BACTERIOPHAGE AND BACTERIOCIN TYPING SCHEME FOR CLOSTRIDIUM-DIFFICILE [J].
SELL, TL ;
SCHABERG, DR ;
FEKETY, FR .
JOURNAL OF CLINICAL MICROBIOLOGY, 1983, 17 (06) :1148-1152
[10]   Clinical impact and associated costs of Clostridium difficile-associated disease [J].
Spencer, RC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 :5-12
12